[Analysis of side effects of a combination chemotherapy of cisplatin and adriamycin in gynecological malignancies: comparison between intravenous and intraarterial administration].
In 23 cases of gynecological malignancies, comparative analysis of the side effects of a combination chemotherapy of cisplatinum (CDDP) and adriamycin (ADM) was performed in terms of administration routes: intravenous and intraarterial. 50 mg/m2 of CDDP and 50 mg/m2 of ADM were administered intravenously once for three weeks. 12.5 mg of CDDP and 10 mg of ADM per one catheter were infused intraarterially once or twice a week. More than severe leukocytopenia was observed in all cases of systemic administration, while in 25% of intraarterial infusion. In 90% of intravenous administration and in about a half of intraarterial cases, thrombocytopenia was noted. Myelosuppression was severest at 10 the to 12th day after administration. The value of creatinine clearance (C-Cr) was within normal limits in 10% of cases of intravenous and in nearly 50% of cases of intraarterial administration. No mortal cases due to myelosuppression and no renal failure ware observed. Most cases of intravenous administration were suffered from severe vomiting, while only in half cases of intraarterial chemotherapy milder emesis appeared. Antiemetic drugs should be administered at least for one week after systemic chemotherapy, and also intraarterial chemotherapy, if necessary.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects*; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007261:Infusions, Intra-Arterial; D007263:Infusions, Parenteral; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy; D014594:Uterine Neoplasms / Q000188:drug therapy*
D004317:Doxorubicin; D002945:Cisplatin